10 bagger
12 years ago
APOLLO MEDICAL HOLDINGS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
Three months ended July 31, Six months ended July 31,
2012 2011 2012 2011
REVENUES $ 1,649,451 $ 1,093,708 $ 3,281,295 $ 2,133,400
COST OF SERVICES 1,205,673 939,336 2,534,332 1,886,825
GROSS PROFIT 443,778 154,371 746,963 246,575
Operating expenses:
General and administrative 501,858 235,130 853,405 511,485
Depreciation 4,946 2,580 9,737 5,873
Total operating expenses 506,804 237,710 863,142 517,358
LOSS FROM OPERATIONS (63,026 ) (83,339 ) (116,179 ) (270,783 )
Other income (expense)
Loss on change in fair value of derivative liabilities (2,914,549 ) - (2,790,711 ) -
Interest expense (205,221 ) (31,603 ) (408,047 ) (63,177 )
Financing cost (19,685 ) (9,375 ) (40,895 ) (18,750 )
Other income 455 1,484 450 2,546
Total other expenses (3,139,000 ) (39,494 ) (3,239,203 ) (79,381 )
LOSS BEFORE INCOME TAXES (3,202,026 ) (122,833 ) (3,355,382 ) (350,164 )
Provision for Income Tax 800 - 4,800 1,600
NET LOSS $ (3,202,826 ) $ (122,833 ) $ (3,360,182 ) $ (351,764 )
WEIGHTED AVERAGE SHARES OF COMMON STOCK OUTSTANDING,
BASIC AND DILUTED 31,015,904 28,985,774 30,780,543 28,819,752
BASIC AND DILUTED NET LOSS PER SHARE $ (0.10 ) $ (0.00 ) $ (0.11 ) $ (0.01 )
10 bagger
13 years ago
AMEH.. $0.10.. 10Q For the three months ended April 30, 2012
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following management’s discussion and analysis should be read in conjunction with the unaudited condensed consolidated financial statements and the notes thereto included in this Quarterly Report. In addition, reference is made to our audited consolidated financial statements and notes thereto and related Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our most recent Annual Report on Form 10-K for the year ended January 31, 2012, filed with the Securities and Exchange Commission ( SEC) on May 15, 2012.
In this Quarterly Report, unless otherwise expressly stated or the context otherwise requires, “Apollo,” “we,” “us” and “our” refer to Apollo Medical Holdings, Inc,, a Delaware corporation, and its wholly-owned subsidiary-management company, Apollo Medical Management, Inc., and affiliated medical groups. Our affiliated professional organizations are separate legal entities that provide physician services in California and with which we have management agreements. For financial reporting purposes we consolidate the revenues and expenses of all our practice groups that we own or manage because we have a controlling financial interest in these practices based on applicable accounting rules and as described in our accompanying financial statements. Also, unless otherwise expressly stated or the context otherwise requires, “our affiliated hospitalists” refer to physicians employed or contracted by either our wholly-owned subsidiaries or our affiliated professional organizations. References to “practices” or “practice groups” refer to our subsidiary-management company and the affiliated professional organizations of Apollo that provide medical services, unless otherwise expressly stated or the context otherwise requires.
The following discussion contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding future events and the future results of Apollo that are based on management’s current expectations, estimates, projections, and assumptions about our business. Words such as “may,” “will,” “could,” “should,” “target,” “potential,” “project,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “sees,” “estimates” and variations of such words and similar expressions are intended to identify such forward-looking statements. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including, but not limited to, those discussed in our most recent Annual Report on Form 10-K, including the section entitled “Risk Factors”, as well as those discussed from time to time in the Company’s other SEC filings and reports. In addition, such statements could be affected by general industry and market conditions. Such forward-looking statements speak only as of the date of this Quarterly Report or, in the case of any document incorporated by reference, the date of that document, and we do not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this Report, or for changes made to this document by wire services or Internet service providers. If we update or correct one or more forward-looking statements, investors and others should not conclude that we will make additional updates or corrections with respect to other forward-looking statements.
Overview
We are a leading provider of hospitalist services in the Greater Los Angeles, California area. Hospitalist medicine is organized around the admission and care of patients in an inpatient facility such as a hospital or skilled nursing facility and is focused on, managing and coordinating the care of hospitalized patients.
Executive Summary
For the three months ended April 30, 2012, the Company’s executive management and certain of our physicians were focused on several forward-looking initiatives, including efforts in obtaining Company designation as an Accountable Care Organization (“ACO”) as defined under the Medicare Shared Savings Program (Section 3022 of the PPACA) (“MSSP”). The ACO concept places a degree of financial responsibility on the providers in hopes of improving care management and limiting unnecessary expenditures while continuing to provide patients freedom to selection of their medical services. The Company believes that in establishing an ACO, ApolloMed will be able to leverage its medical management expertise to efficiently managed patient’s costs through improved communication between physicians and their patients, which should lead to improved patient outcomes and lower readmission rates. The Company is working closely with the Center for Medicare and Medicaid Services, and we expect to hear a response to our ACO application in the second or third quarter of fiscal 2013. ACOs participating in the shared-savings payment model will be able to share in up to 50 percent of their achieved savings, depending on how well they exceed minimum quality performance standards. If successful in obtaining a ACO designation, ApolloMed may be required to raise additional capital to fund this opportunity.
We incurred a loss from operations of $53,153 for the three months ended April 30, 2012, compared to a loss from operations of $187,444 for the three months ended April 30, 2011. To date the Company has funded its operations from internally generated cash flow and external sources, the proceeds from the Senior Secured Note and the proceeds available from the private placement of convertible notes which have provided funds for near-term operations and growth. The current operating plan indicates that losses from operations may be incurred for all of fiscal 2013 and maturing debt in fiscal 2013 totaling $1,520,000. Consequently, we may not have sufficient liquidity necessary to sustain operations for the next twelve months and this raises substantial doubt that we will be able to continue as a going concern. The Company intends to seek raise additional capital through public or private equity financings, partnerships, joint ventures, disposition of assets, debt financings, bank borrowings or other sources of financing.
No assurances can be made that management will be successful in achieving its plan. If the Company is not able to raise substantial additional capital in a timely manner, the Company may be forced to cease operations.
Results of Operations and Operating Data
Three Months Ended April 30, 2012 vs. Three Months Ended April 30, 2011
Net revenues for the three months ended April 30, 2012 of $1,631,844 increased $592,151, or 57 percent, over net revenues of $1,039,693 reported for the three months ended April 30, 2011 due to the Company’s acquisitions and growth of fee for service revenues in new attributable to new hospital contracts, and expansion of services with existing medical group clients at new hospitals. Net revenues are comprised of net billings under the various fee structures from health plans, medical groups/IPA’s and hospitals, and income from service fee agreements.
Cost of services includes the payroll and consulting costs of the physicians, all payroll related costs, costs for all medical malpractice insurance and physician privileges. Cost of services was $1,328,659 for the three months ended April 30, 2012,or 84% of revenues, compared to $947,849 for the three months ended April 30, 2011, or 91% of revenues. The increase of $381,170 is attributable to $239,299 increase in physician costs attributable to new physicians hired to support new contracts, $36,441 increase in non-cash stock compensation, $33,402 increase related to the acquisition of PCCM and consolidation of LALC, and $72,028 in other cost related to supporting growth in new contracts and expansion of services.
General and administrative expenses include all salaries, benefits, supplies and operating expenses, not specifically related to the day-to-day operations of our physician group practices, including billing and collections functions, and our corporate management and overhead. During the three months ended April 30, 2012, the Company’s executive management and certain of our physicians were active in seeking Company ACO designation. General and administrative expenses were $351,547, or 22% of revenues, for the three months ended April 30, 2012 compared to $276,355 for the three months ended April 30, 2011, or 27% of revenues. The increase of $75,192 is primarily the result of an increase in professional fees of $20,365 costs to support the continuing growth of our operations, $16,683 increase in salaries and wages to support in-house medical billing initiative, $6,500 increase in compensation due to the addition of two new directors to the Company’s board of directors, $20,680 in additional administrative expenses due to the acquisition of PCCM and consolidation of LALC, and $10,964 in additional support other Company initiatives.
Depreciation and amortization expense was $4,791 for the three months ended April 30, 2012, and $3,293 for the three months ended April 30, 2011, primarily due to the addition of the Company’s investment in a new billing system.
Loss from operations was $53,153 for the three months ended April 30, 2012 compared to a loss from operations of $187,444 in the same period in 2011, a decrease of $134,291 due to improvements in 2012 revenues and gross profit while adding contracts with hospitals, IPAs and Health plans and the hiring of several additional physicians.
Gain on change in fair value of warrant and derivative liabilities of $123,838 for three months ended April 30, 2012 reflects the change in the fair value of the Company’s warrant and derivative liabilities at April 30, 2012 and January 31, 2012.
Interest expense and financing cost was $224,036 for the three months ended April 30, 2012, compared to $40,949 for the three months ended April 30, 2011. The increase of $183,087 was due to higher discount amortization $163,458, higher interest expense due to the Senior Secured Notes $16,835, and $7,794 due to other borrowings.
Net loss was $157,356 for the three months ended April 30, 2012, compared to a net loss of $228,930 for the three months ended April 30, 2011. The decrease in the net loss of $71,574 is primarily related to increase in revenue growth and lower cost of services as a percentage of revenue.
Liquidity and Capital Resources
At April 30, 2012, the Company had cash and cash equivalents of $193,931, compared to cash and cash equivalents of $164,361 at January 31, 2012. The Company has borrowings totaling $1,520,000 that mature within one year and $150,000 in long-term borrowings at April 30, 2012.
Three months ended April 30, 2012
For the three months ended April 30, 2012, cash used in operations was $131,160. This was substantially a result of net losses of 157,356, cash used in working capital of $143,599, partially offset by non-cash expenses of $169,755. Non-cash expenses primarily include depreciation, issuance of shares of common stock for service, stock option compensation expense, amortization of financing costs, amortization of debt discount, and gain on change in fair value of warrant and derivative liabilities. Cash was used for working capital due to an increase in trade receivables of $152,404, an increase in due from affiliates of $2,425, an increase in financing costs of $5,000, and increase in prepaid expenses and advances of $3,963 and an increase in other assets of $1,450; partially offset by a net increase in due to officers of $6,604, and an increase in accounts payable and accrued liabilities of $15,619.
For the three months ended April 30, 2012, cash used in investing activities was $9,270 related to the Company’s investment in a new billing system and office technology equipment.
For the three months ended April 30, 2012, cash provided by financing activities was $270,000 related to proceeds from the Senior Secured Note. Borrowings were used primarily to fund working capital requirements and technology investments.
Three months ended April 30, 2011
Net cash used in operating activities totaled $114,432 in the three months ended April 30, 2011, compared to net cash used in operations of $155,830 for the comparable three months ended April 30, 2010. The decrease in accounts receivable and increase in and increase in accounts payable, is the primary cause for the decrease in cash used for operating activities and transaction and start-up losses related with acquisition of AHI for the three months ended April 30, 2010.
During the three months ended April 30, 2011, the Company advanced $800 to an affiliated Company. The Company invested $4,568 to develop a web site and an $800 advance to an affiliated Company in the first quarter of 2010.
The Company had $193,931 in cash and cash equivalents at April 30, 2012. We incurred a loss from operations of $53,153 for the three months ended April 30, 2012. To date the Company has funded its operations from internally generated cash flow and external sources, the proceeds from the Senior Secured Note and the proceeds available from the private placement of convertible notes which have provided funds for near-term operations and growth. The current operating plan indicates that losses from operations may be incurred for all of fiscal 2013 and maturing debt in fiscal 2013 totaling $1,520,000. Consequently, we may not have sufficient liquidity necessary to sustain operations for the next twelve months and this raises substantial doubt that we will be able to continue as a going concern. The Company intends to seek raise additional capital through public or private equity financings, partnerships, joint ventures, disposition of assets, debt financings, bank borrowings or other sources of financing. No assurances can be made that management will be successful in achieving its plan. If the Company is not able to raise substantial additional capital in a timely manner, the Company may be forced to cease operations.
10 bagger
13 years ago
AMEH $0.10..
Apollo Medical Holdings, Inc. Appoints Gary Augusta to Board of Directors... Finance and Business Development Expert Will Help Drive Healthcare Services Growth...
GLENDALE, Calif., March 7, 2012 /PRNewswire/ -- Apollo Medical Holdings, Inc. ("ApolloMed") (OTC-AMEH), a leading provider of hospitalist, critical care and multi-disciplinary care management services to the healthcare community, today announced the appointment of Gary Augusta to its Board of Directors. In addition, Mr. Augusta's investment firm - SpaGus Capital Partners - has agreed to provide ApolloMed with working capital.
Mr. Augusta brings more than 20 years of experience as an executive focused on private equity, growth strategy, operations, corporate development and M&A at companies ranging from start-up ventures to Fortune 500 companies. He is also an experienced investor and operator of growth businesses.
"Gary brings a wide scope of experience and expertise that will help ApolloMed earn a growing share of the $650 billion spent annually in the U.S. on inpatient hospital care," stated Warren Hosseinion, M.D., Chief Executive Officer of Apollo Medical Holdings, Inc. "His hands-on approach, business and investor network and ability to execute will benefit us tremendously."
Mr. Augusta currently serves as President of SpaGus Ventures LLC and SpaGus Capital Partners, growth funds that invest in life sciences and technology companies. He previously co-founded and served as President and CEO of OCTANe, an innovation development corporation formed to start and fund biomedical, technology, green tech and other types of innovative startup companies.
"I look forward to working with Warren and the talented ApolloMed team to help take the company to the next level," stated Gary Augusta. "ApolloMed's unique patient-centric, results-driven inpatient and post-discharge care delivery model positions it as a leader in this market."
Earlier in his career, Mr. Augusta was Vice President of M&A and Corporate Development at engineering and construction giant Fluor, where he focused on internal new business creation and mergers and acquisitions. Prior to his tenure at Fluor, he served as a principal at global management consulting firm A.T. Kearney, where he focused on growth strategy, operational improvement and change management assignments for clients including Prudential Healthcare, FedEx, Wachovia and many others.
Other posts include serving as Executive Director of the OCTANe Foundation for Innovation, and member of the UC Irvine CEO Roundtable, the Keck Graduate Institute Advisory Council and the UC Irvine Advisory Boards for both the School of Engineering and the School of Information & Computer Science. He serves as a board member or advisor to several start-up companies in the biomedical and technology industries, as well as board director for a publicly traded micro-cap company.
Mr. Augusta resides in Southern California. He earned a BS in Mechanical Engineering from the University of Rhode Island and a Master of Science and Management (MSM) from Georgia Tech.
About Apollo Medical Holdings, Inc.
ApolloMed is a leading provider of integrated medical management services that improve the quality and efficiency in inpatient hospital care. The Company's integrated model combines hospitalist medicine, critical care medicine, 24-hour physician call centers, case management and transition management. Its mission is to improve care and efficiency, while helping healthcare organizations engage in performance payments and shared accountability arrangements. The company's strategy is to capitalize on the growing market for hospital-based physician and care management services. There are currently 4,900 acute care hospitals in the U.S., with more than 35 million annual admissions. Total U.S. spending on hospital care currently exceeds $650 billion and is expected to increase to $1.3 trillion by 2016. For more information, please visit www.apollomed.net.
Media Contacts:
Erik Deutsch
ExcelPR Group (for ApolloMed)
(323) 851-2300 x112
erikd[at]excelpr[dot]com
Nidia Flores
Operations Manager
Apollo Medical Holdings, Inc.
(818) 844-3881
n.flores[at]apollomed[dot]net
SOURCE Apollo Medical Holdings, Inc.
Level up your trading with our powerful tools and real-time insights all in one place.
Ask ADVFN Intelligence (AI)
Renee
7 years ago
stocktrademan
9 years ago
Hegotgame
12 years ago
greasemonkeyshoes
12 years ago
Hot Features
Premium
